Evaluation of Blood Pressure in Children Treated with Ceftriaxone: A Case-Control Study
DOI:
https://doi.org/10.35516/jjps.v16i3.1608Keywords:
ceftriaxone, hypertension, blood pressure, nephrolithiasis, childrenAbstract
Background: In children, high blood pressure can develop into hypertension and its consequences during puberty and adulthood. High blood pressure in children is often secondary to other causes, including renal diseases. Nephrolithiasis is one of the causes of secondary hypertension. The extensive use of cephalosporins in hospitals, particularly ceftriaxone, can result in nephrolithiasis. Therefore, the purpose of this study was to assess the relationship between ceftriaxone treatment and elevated blood pressure in children.
Method: The research was conducted as a case-control study over an 18-month period from 2018 to 2019. In this study, blood pressure was measured in 111 children aged 3-13 years who were hospitalized at Amir Kabir Hospital in Arak and received ceftriaxone for at least 48 hours. As a control group, 111 children who did not receive ceftriaxone had their blood pressure measured. The blood pressure levels and percentiles of children in the two groups were then compared.
Result: In the case and control groups, the mean age was 5.1±1.61 and 6.04±2.4 years, and the mean height was 109.17±10.71 and 114.86±12.95 cm, respectively. A slightly higher mean systolic blood pressure percentile was observed in the case group (65.59±18.17) than in the control group (65.28±14.51) (P=0.112), and the mean diastolic blood pressure percentile was also slightly higher in the case group (58.89±18.88) than in the control group (54.85±19.28) (P=0.317). The difference in diastolic blood pressure was greater than in systolic blood pressure. However, these detected differences were slight and not statistically significant.
Conclusion: This study showed no association between blood pressure levels and ceftriaxone treatment in children older than three years who received the medicine for at least 48 hours. However, additional research is suggested, focusing on the effects of the medicine at higher doses and over a longer period of time following administration.
References
Zhou B., Carrillo-Larco RM., Danaei G., Riley LM., Paciorek CJ., Stevens GA., et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet. 2021; 398(10304): 957-80. DOI: https://doi.org/10.1016/S0140-6736(21)01330-1
Bouhanick B., Sosner P., Brochard K., Mounier-Véhier C., Plu-Bureau G., Hascoet S., et al. Hypertension in Children and Adolescents: A Position Statement From a Panel of Multidisciplinary Experts Coordinated by the French Society of Hypertension. Frontiers in Pediatrics. 2021; 9. DOI: https://doi.org/10.3389/fped.2021.680803
Jameson JL., Kasper DL., Longo DL., Fauci AS., Hauser SL., Loscalzo J. Harrison's Principles of Internal Medicine, 20th ed. Ohio: McGraw-Hill Education. 2018.
Noubiap JJ., Essouma M., Bigna JJ., Jingi AM., Aminde LN., Nansseu JR. Prevalence of elevated blood pressure in children and adolescents in Africa: a systematic review and meta-analysis. The Lancet Public Health. 2017; 2(8): e375-e86. DOI: https://doi.org/10.1016/S2468-2667(17)30123-8
Kliegman RM., Stanton BF., Geme JWS., Schor NF. Nelson Textbook of Pediatrics 21st ed. Philadelphia. Elsevier. 2020.
Charles L., Triscott J., Dobbs B. Secondary Hypertension: Discovering the Underlying Cause. Am Fam Physician. 2017; 96(7): 453-61.
Chrysaidou K., Chainoglou A., Karava V., Dotis J., Printza N., Stabouli S. Secondary Hypertension in Children and Adolescents: Novel Insights. Curr Hypertens Rev. 2020; 16(1): 37-44. DOI: https://doi.org/10.2174/1573402115666190416152820
Mattoo TK. Epidemiology, risk factors, and etiology of hypertension in children and adolescents. In: UpToDate.Post TW (ed): UpToDate, Waltham, MA. (Accessed on Jan 16, 2019). DOI: https://doi.org/10.1097/01.COT.0000584144.73776.ab
Whelton PK., Carey RM., Aronow WS., Casey DE., Collins KJ., Dennison Himmelfarb C., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018; 71(19): e127-e248. DOI: https://doi.org/10.1016/j.jacc.2017.11.006
Al-Dujaili E., Abu Hajleh M., Al-Turk W. Effect of Green Coffee Bean Extract Consumption on Blood Pressure and Anthropometric Measures in Healthy Volunteers : A Pilot Crossover Placebo Controlled Study. Jordan Journal of Pharmaceutical Sciences. 2016; 9: 181-91. DOI: https://doi.org/10.12816/0033383
Whelton PK., Carey RM., Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71(19): e127-e248. DOI: https://doi.org/10.1161/HYP.0000000000000076
Bucher BS., Ferrarini A., Weber N., Bullo M., Bianchetti MG., Simonetti GD. Primary Hypertension in Childhood. Current Hypertension Reports. 2013; 15(5): 444-52. DOI: https://doi.org/10.1007/s11906-013-0378-8
Yan W., Li X., Zhang Y., Niu D., Mu K., Ye Y., et al. Reevaluate secular trends of body size measurements and prevalence of hypertension among Chinese children and adolescents in past two decades. Journal of hypertension. 2016; 34(12): 2337-43. DOI: https://doi.org/10.1097/HJH.0000000000001114
Letourneau AR. Cephalosporins. In: UpToDate.Post TW (ed): UpToDate, Waltham, MA. (Accessed on Jun 19, 2018). DOI: https://doi.org/10.1097/01.COT.0000550758.49876.18
Al-Momani I., Thalji M. Indirect Flow-Injection Spectrophotometric Determination of Some B-Lactam Antibiotics. Jordan Journal of Pharmaceutical Sciences. 2021; 14: 127-35.
Standing JF., Ongas MO., Ogwang C., Kagwanja N., Murunga S., Mwaringa S., et al. Dosing of Ceftriaxone and Metronidazole for Children With Severe Acute Malnutrition. Clin Pharmacol Ther. 2018; 104(6): 1165-74. DOI: https://doi.org/10.1002/cpt.1078
Katzung BG. Basic & Clinical Pharmacology 14th ed. New York: McGraw-Hill Education. 2018.
Romano A. Cephalosporin allergy: Clinical manifestations and diagnosis. In: UpToDate.Post TW (ed):UpToDate, Waltham, MA. (Accessed on Jun 17, 2014).
Youssef DM., Sherief LM., Sherbiny HS., ElAttar MY., Sheikh ARME., Fawzy FM., et al. Prospective study of nephrolithiasis occurrence in children receiving cefotriaxone. Nephrology. 2016; 21(5): 432-7. DOI: https://doi.org/10.1111/nep.12625
Mohkam M., Karimi A., Gharib A., Daneshmand H., Khatami A., Ghojevand N., et al. Ceftriaxone associated nephrolithiasis: a prospective study in 284 children. Pediatric Nephrology. 2007; 22(5): 690-4. DOI: https://doi.org/10.1007/s00467-006-0401-2
Ustyol L., Bulut M., Agengin K., Bala K., Yavuz A., Bora A., et al. Comparative evaluation of ceftriaxone- and cefotaxime-induced biliary pseudolithiasis or nephrolithiasis: A prospective study in 154 children. Human & Experimental Toxicology. 2017; 36(6): 547-53. DOI: https://doi.org/10.1177/0960327116658108
Li N., Zhou X., Yuan J., Chen G., Jiang H., Zhang W. Ceftriaxone and Acute Renal Failure in Children. Pediatrics. 2014; 133(4): e917-e22. DOI: https://doi.org/10.1542/peds.2013-2103
Ollivier J., Carrié C., d'Houdain N., Djabarouti S., Petit L., Xuereb F., et al. Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance? Antimicrob Agents Chemother. 2019; 63(3). DOI: https://doi.org/10.1128/AAC.02134-18
Cupisti A., D’Alessandro C., Samoni S., Meola M., Egidi MF. Nephrolithiasis and hypertension: possible links and clinical implications. Journal of Nephrology. 2014; 27(5): 477-82. DOI: https://doi.org/10.1007/s40620-014-0068-x
Tran AH., Urbina EM. Hypertension in children. Current Opinion in Cardiology. 2020; 35(4): 376-80. DOI: https://doi.org/10.1097/HCO.0000000000000744
Song BM., Kim HC., Shim J-S., Lee MH., Choi DP. Inter-arm difference in brachial blood pressure in the general population of Koreans. Korean Circulation Journal. 2016; 46(3): 374-83. DOI: https://doi.org/10.4070/kcj.2016.46.3.374
Song BM., Kim HC., Shim J-S., Kang DR. Comparison between right and left upper arms in detection of hypertension. Korean Circulation Journal. 2019; 49(3): 267-77. DOI: https://doi.org/10.4070/kcj.2018.0147
The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114 (2 Suppl 4th Report): 555-76. DOI: https://doi.org/10.1542/peds.114.2.S2.555
CDC. CDC growth charts for children age 2 years and older in the U.S 2010 [Available at: https://www.cdc.gov/growthcharts /].
Azarkar G., Birjand MM., Ehsanbakhsh A., Bijari B., Abedini MR., Ziaee M. Ceftriaxone-associated nephrolithiasis and gallstone in adults. Drug, healthcare and patient safety. 2018; 10: 103. DOI: https://doi.org/10.2147/DHPS.S183892
Wang S., Huang X., Xu Q., Xu T. Research progress of mechanisms of ceftriaxone associated nephrolithiasis. Mini reviews in medicinal chemistry. 2017; 17(17): 1584-7. DOI: https://doi.org/10.2174/1389557516666160801092713
Chutipongtanate S., Thongboonkerd V. Ceftriaxone crystallization and its potential role in kidney stone formation. Biochemical and biophysical research communications. 2011; 406(3): 396-402. DOI: https://doi.org/10.1016/j.bbrc.2011.02.053
Fesharakinia A., Ehsanbakhsh A-R., Ghorashadizadeh N. Ceftriaxone–Associated Nephrolithiasis in Children. Iranian Journal of Pediatrics. 2013; 23(6): 643.
Shang W., Li Y., Ren Y., Yang Y., Li H., Dong J. Nephrolithiasis and risk of hypertension: a meta-analysis of observational studies. BMC Nephrology. 2017; 18(1): 344. DOI: https://doi.org/10.1186/s12882-017-0762-8
Kimata T., Kaneko K., Takahashi M., Hirabayashi M., Shimo T., Kino M. Increased urinary calcium excretion caused by ceftriaxone: possible association with urolithiasis. Pediatric Nephrology. 2012; 27(4): 605-9. DOI: https://doi.org/10.1007/s00467-011-2038-z
Chatchen S., Pongsakul N., Srisomsap C., Chiangjong W., Hongeng S., Svasti J., et al. Unravelling Pathophysiology of Crystalline Nephropathy in Ceftriaxone-Associated Acute Kidney Injury: A Cellular Proteomic Approach. Nephron. 2018; 139(1): 70-82. DOI: https://doi.org/10.1159/000486324
James MT., Grams ME., Woodward M., Elley CR., Green JA., Wheeler DC., et al. A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury. American Journal of Kidney Diseases. 2015; 66(4): 602-12. DOI: https://doi.org/10.1053/j.ajkd.2015.02.338
Chawla LS., Eggers PW., Star RA., Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. New England Journal of Medicine. 2014; 371(1): 58-66. DOI: https://doi.org/10.1056/NEJMra1214243
Reaffirmation of AAP Clinical Practice Guideline: The Diagnosis and Management of the Initial Urinary Tract Infection in Febrile Infants and Young Children 2-24 Months of Age. Pediatrics. 2016; 138(6). DOI: https://doi.org/10.1542/peds.2016-3026
Olson PD., McLellan LK., Liu A., Briden KE., Tiemann KM., Daugherty AL., et al. Renal scar formation and kidney function following antibiotic-treated murine pyelonephritis. Dis Model Mech. 2017; 10(11): 1371-9. DOI: https://doi.org/10.1242/dmm.036798
